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Sensitive high-throughput neutralization assays, based upon pseudoviruses carrying a secreted alkaline phosphatase (SEAP) reporter
gene, were developed and validated for human papillomavirus (HPV)16, HPV18, and bovine papillomavirus 1 (BPV1). SEAP pseudoviruses
were produced by transient transfection of codon-modified papillomavirus structural genes into an SV40 T antigen expressing line derived
from 293 cells, yielding sufficient pseudovirus from one flask for thousands of titrations. In a 96-well plate format, in this initial
characterization, the assay was reproducible and appears to be as sensitive as, but more specific than, a standard papillomavirus-like particle
(VLP)-based enzyme-linked immunosorbent assay (ELISA). The neutralization assay detected type-specific HPV16 or HPV18 neutralizing
antibodies (titers of 160–10240) in sera of the majority of a group of women infected with the corresponding HPV type, but not in virgin
women. Sera from HPV16 VLP vaccinees had high anti-HPV16 neutralizing titers (mean: 45000; range: 5120–163840), but no anti-HPV18
neutralizing activity. The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective
antibody responses in HPV natural history and prophylactic vaccine studies.
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Introduction ing, with immune responses to earlier HPV exposure per-Human papillomaviruses (HPVs), which compose a
group of more than 100 genotypes, cause genital and
cutaneous warts (reviewed in (Fazel et al., 1999; Handsfield,
1997; Lowy and Howley, 2001)). A subset of HPV geno-
types, especially HPV16 and HPV18, has been implicated
in the etiology of cervical cancer (Bosch and de Sanjose,
2003; Bosch et al., 1995). Even for those HPV genotypes
associated with cancer, most HPV infections are self-limit-0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2003.12.027
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E-mail address: schillej@dc37a.nci.nih.gov (J.T. Schiller).haps contributing to the relative resistance of older
individuals to the acquisition of HPV (Koutsky et al.,
1992; Schiffman, 1994).
In other viral infections, resistance to infection may
correlate with the development of neutralizing antibodies.
Such data have been difficult to obtain with HPV
infection because HPV neutralization assays are cumber-
some, and most lack sufficient sensitivity to reliably
detect serum-neutralizing antibodies following natural
infection. Currently available papillomavirus neutraliza-
tion assays rely on neutralization of either authentic
virions (Christensen et al., 1992; Smith et al., 1995;
White et al., 1998), pseudotyped virions (Roden et al.,
1996a), pseudovirions that have encapsidated reporter
genes (Kawana et al., 1998; Rossi et al., 2000; Stauffer
D.V. Pastrana et al. / Virology 321 (2004) 205–216206et al., 1998; Touze and Coursaget, 1998; Unckell et al.,
1997), or capsids carrying a reporter gene on their
surface (Bousarghin et al., 2002). Most serological anal-
yses of responses to natural HPV infection have relied on
assays that are surrogates for neutralization, especially
virus-like particle (VLP)-based enzyme-linked immuno-
sorbent assays (ELISAs) (Dillner, 1999) or antibody
displacement assays (Opalka et al., 2003; Yeager et al.,
2000). These surrogate assays are more sensitive than
most current neutralization assays and are simple enough
that they can be used to analyze hundreds of samples.
However, one problem with VLP-based ELISAs is that
while the immunodominant neutralization epitopes of
HPVs have been shown to be genotype-specific, ELISAs
may also detect non-neutralizing and cross-genotype re-
active antibodies, thus complicating the interpretation of
some results.
The development of prophylactic HPV vaccines repre-
sents another area of active investigation in which the
measurement of serologic responses plays a key role. The
leading candidate prophylactic vaccine is composed of
the L1 major capsid protein assembled into VLPs that
possess the type-specific immunodominant neutralization
epitopes present in authentic virions. In preclinical vac-
cine studies involving animal papillomavirus challenge,
L1 VLP immunization conferred high-level protection
attributable to type-specific neutralizing antibodies (Breit-
burd et al., 1995; Christensen et al., 1996b; Kirnbauer et
al., 1996; Suzich et al., 1995). Early phase trials in
humans have confirmed that L1 VLP vaccines are well
tolerated and immunogenic, and that an HPV16 L1 VLP
vaccine may protect against HPV16 infection (Koutsky et
al., 2002) (also reviewed in (Galloway, 2003; Schiller and
Lowy, 2001; Stanley, 2002)). As with natural history
studies, most vaccine responses have been determined
by VLP ELISA or other surrogate assays. Because it is
expected that commercialized L1 VLP vaccines will be
composed of VLPs from two or more HPV types, the
partial cross-genotype reactivity of VLP-based ELISAs
might compromise their utility.
These considerations suggest that a scalable papillo-
mavirus neutralization assay with sensitivity comparable
to VLP-based ELISAs would have utility for natural
history studies of HPV infection and for the analysis of
vaccine responses. We have recently described (Buck et
al., 2004) the development of a new procedure for the
intracellular generation of papillomavirus pseudoviruses
(also known as papillomaviral vectors) whose production
efficiency was at least 10 million-fold greater than that of
our previous method of intracellular pseudovirus produc-
tion (Roden et al., 1996a). In this communication, we
report the application of this technology to the develop-
ment and validation of a quantitative high-throughput
papillomavirus neutralization assay by analyzing the se-
rum neutralization titers of VLP-vaccinated women and
women naturally infected with HPV.Results
Neutralization of GFP pseudovirus in C127, HaCaT, and
293TT cells
A method for generating high-titer pseudovirus stocks
composed of a reporter plasmid encapsidated by major and
minor structural proteins (L1 and L2) of bovine papilloma-
virus 1 (BPV1) and HPV16 has recently become available
(C.B. Buck et al., 2004). The method depends on the high-
level coexpression of L1 and L2 and overreplication of a
reporter plasmid carrying the SV40 origin of replication
(SV40 ori) in a cell line, 293TT, engineered to overexpress
the SV40 T antigen. To determine if such pseudoviruses
could be adapted to an in vitro neutralization assay, we
generated an HPV16 pseudovirus containing a plasmid
encoding a green fluorescent protein (GFP) reporter gene
and the SV40 ori. A crude pseudovirus stock was generated
by cotransfecting this GFP reporter plasmid, pYafW, into
293TT cells together with plasmids expressing codon-mod-
ified HPV16L1 (p16L1h) and HPV16L2 (p16L2h) genes
(Leder et al., 2001).
We used the HPV16-based GFP pseudovirus at a dilution
of 1:2500 to infect several lines, namely mouse C127,
human HaCaT keratinocytes, and 293TT cells (Table 1).
FACS analysis of the cells showed that each line could be
infected with the pseudovirus and that infection could be
neutralized by preincubating the pseudovirus inoculum with
an HPV16-neutralizing monoclonal antibody (V5). The
neutralization titer for the monoclonal antibody was about
two million in each line. Neutralization was HPV16 anti-
body specific, in that an anti-BPV1 monoclonal antibody
(5B6) failed to prevent infection by the pseudovirus. Com-
pared with infection of C127 cells, the mean fluorescence in
infected HaCaT cells was about 2-fold higher, while in
293TT cells there were 4–5-fold more GFP-expressing cells
and a 14–35-fold higher mean fluorescence. Both increases
in the 293TT cells probably reflect the ability of the GFP
plasmid to be overreplicated by the high levels of SV40 T
antigen in these cells. This higher signal strength in 293TT
cells suggested that this line would be the preferred indicator
cell for a neutralization assay.
Secreted alkaline phosphatase pseudovirus neutralization
assay
The GFP pseudovirus assay represented a substantial
improvement over our previous focus assay in terms of
ease of pseudovirus production and shortening of assay
time. To develop an assay with even higher throughput,
we sought an alternative readout that might be easier to
monitor than FACS-based GFP detection. For this purpose,
we constructed a pseudovirus encoding secreted alkaline
phosphatase (SEAP) which can be detected using a highly
sensitive chemiluminescent reporter system. SEAP is se-
creted into cell-culture supernatants, thus reducing handling
Fig. 1. Effect of SV40 large T antigen on SEAP production after
pseudovirion infection. Infection of 293H (solid bars) or 293TT (striped
bars) cells with pYSEAP pseudovirions. Two-fold increasing concentra-
tions of diluted pseudovirions were used to infect cells. After 72 h, SEAP in
the supernatant of infected cells was assayed by luminometry. Numbers on
top of the bars represent the mean of 6 wells, and error bars are the standard
error of the mean.
Table 1
Antibody-dependent neutralization of infection with GFP HPV16
pseudovirus
Cell type Treatment Mean
fluorescence
Percentage of
FL1-positive
cells
Percentage of
neutralizationa
C127 No pseudovirus 9 0.1 NA
Pseudovirus +
No Ab
20 10.2 0
V5 at 1:5  104 10 0.2 100
V5 at
1:2.5  106
18 4.6 66
V5 at
1:1.25  108
20 9.6 7
5B6 at
1:5  104
22 11.8 0
HaCaT No pseudovirus 21 0.3 NA
Pseudovirus +
No Ab
49 7.8 0
V5 at 1:5  104 18 0.4 100
V5 at
1:2.5  106
40 3.0 65
V5 at
1:1.25  108
51 9.0 0
5B6 at
1:5  104
50 9.7 0
293TT No pseudovirus 21 0.3 NA
Pseudovirus +
No Ab
710 44.2 0
V5 at 1:5  104 19 0.7 99
V5 at
1:2.5  106
512 32.8 26
V5 at
1:1.25  108
647 44.6 0
5B6 at
1:5  104
690 45.0 0
a Percent neutralization was defined as +100 minus the ratio of the specific
percentage of cells that were FL1-positive with V5 (obtained by subtracting
background percentage of FL1-positive cells with no pseudovirus) divided
by the specific percentage of cells that were positive without antibody
(obtained by subtracting background percentage of FL1-positive cells with
no pseudovirus) were FL1 positive with V5 divided by the percent of cells
that were positive without antibody. were FL1 positive with V5 divided by
the percent of cells that were positive without antibody.
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more than several days.
In preliminary experiments, we compared SEAP ex-
pression from an HPV16 pseudovirus containing a com-
mercially available plasmid, pSEAP2Control (SEAP
expression is under the control of SV40 early promoter),
to pseudoviruses carrying two newly constructed SEAP
reporter plasmids; p2CMVSEAP (SEAP expression is
under the control of CMV immediate early promoter)
and pYSEAP (uses human elongation factor-1a (EF1-a)
promoter). Each of the three plasmids also contains the
SV40 ori. We found that 293TT target cells infected with
the pseudovirus containing pYSEAP expressed approxi-
mately 10 or 100 times more SEAP (measured as rela-
tively light units, RLU) than cells infected with
p2CMVSEAP or pSEAP2Control, respectively (data not
shown).To determine the degree to which replication of pYSEAP
by SV40 T antigen enhanced SEAP production, we trans-
duced 293H (T antigen-negative) or 293TT (T antigen-
positive) cells with a pYSEAP pseudovirus preparation. In
preliminary studies, we found that SEAP was not detectable
at 24 h posttransduction in either cell line, consistent with
previous observations that papillomavirus infection, as well
as pseudovirus transduction, is a relatively slow process (Day
et al., 2003) (C.B. Buck et al., 2004). SEAP was readily
detected in both lines by 48 h posttransduction, and its
concentration increased about 8-fold at 72 h, with a further
3-fold increase at 96 h, where it plateaued. In view of this time
course, we chose to assay SEAP production at 72 h postin-
fection in subsequent assays.When the 293H and 293TTcells
were infected with 2-fold serial dilutions of pYSEAP HPV16
pseudovirus, there was an approximately linear response for
RLU readouts between 20 and 500 (Fig. 1 and data not
shown). Analysis of six replicates showed that intra-assay
variation in SEAP production had a standard error of the
mean of approximately 3–4%. At each dilution, 293TT cells
produced approximately 30–40 times more SEAP than 293H
cells. Therefore, 293TT cells were used as target cells for all
subsequent experiments.
In our previous HPV16 neutralization assay (Roden et al.,
1996a), which is based on focal transformation of C127 cells
induced by HPV16 pseudovirions that have encapsidated the
BPV1 genome, we had observed that the apparent neutrali-
zation titer varied inversely with the size of the pseudovirus
inoculum (Pastrana et al., 2001). Thus, the smaller inocula
increased the sensitivity of the assay, but with a lowering of
the signal to background ratio and an eventual loss of the
linear response. To examine the inoculum–sensitivity rela-
tionship in the SEAP neutralization assay, we performed
neutralization with two different concentrations of pYSEAP
HPV16 pseudovirus and serial dilutions of monoclonal
antibodyV5 (Fig. 2). Although the 8-fold larger pseudovirion
inoculum (the 1:100 dilution) resulted in a 7.5-fold rise in
Fig. 2. Effect of inoculum size on neutralization titers. Pseudovirus stock was diluted 1:100 (black bars) or 1:800 (gray bars), preincubated with 10-fold serial
dilutions of V5 Monoclonal Antibody starting at 1:250,000 or with 5B6 at the highest concentration, and used to infect 293TT cells. SEAP activity was
calculated from an average of 3 wells for each condition and 100% activity was set for wells with pseudovirus but without antibody incubation.
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inoculum resulted in more than a 10-fold decrease in neu-
tralizing titer compared with the 1:800 inoculum (the neu-
tralizing titer for the 1:100 dilution wasz2.5 105, andz2.5
 106 for the 1:800 dilution of pseudovirus). Given this trend,
we decided to use pseudovirions at concentrations that would
yield 20–80 RLUs (for this stock 1:800), which represented a
level whose positive signal was reproducibly 30–40 times
above background and in the linear range.
Analysis of sera from HPV16 VLP vaccine trials
We used the SEAP HPV16 pseudovirus assay to deter-
mine the endpoint neutralization titers for sera from 12
volunteers enrolled in a Phase I clinical trial of an HPV16
L1 VLP vaccine (Harro et al., 2001). The serum samples
were obtained 1 month after a series of three intramuscular
inoculations with 50-Ag doses of VLPs without adjuvant. To
examine inter-assay variation, three separate SEAP HPV16
neutralization assays were carried out on different daysTable 2
Sensitivity and reproducibility of the SEAP pseudovirus neutralization assay usin
Patient 16 ELISAa 18 ELISA 16 focus assaya SEAP p
Crude
1
25 10,240 2560 640 10,240
26 10,240 2560 640 20,480
27 10,240 2560 640 20,480
28 40,960 2560 2560 40,960
29b <10 <40 <40 <40
30 10,240 640 640 20,480
31 40,960 2560 10,240 81,920
32 2560 640 160 5120
33b <10 <40 <40 <40
34 40,960 640 2560 81,920
35 40,960 2560 2560 40,960
36 10,240 160 640 10,240
GMT 15,500 1300 1100
Note. Values in the columns reflect the inverse of serum dilution for the endpoin
SEAP compared to the virus added without antibody. GMT represents the geome
a Values for the HPV16 VLP ELISA and the focus neutralization assay were pre
b Placebo-immunized volunteers.(Table 2, columns labeled ‘‘crude’’) using the same pseu-
dovirus stock. The mean neutralization titers for the VLP
vaccinees ranged from 3400 to 68000, and no neutralizing
activity was detected in sera from the two placebo controls.
There was good inter-assay reproducibility using the crude
preparation of pseudovirions, as the same titer for each
volunteer was obtained in at least two out of the three
experiments and most discordant results differed by only 2-
fold. The reproducibility of the assay was statistically
significant, with a rho (q) exceeding 0.93 and a linear
weighted kappa (j) of greater than 0.63.
The sera from the volunteers had previously been tested
by HPV16 ELISA (Harro et al., 2001) and by our previous
HPV16 neutralization assay (Pastrana et al., 2001; Roden et
al., 1996a), which enabled us to compare these results with
the titers obtained in the SEAP assay (Table 2). There was a
good correlation between the titers in the two HPV16
neutralization assays (q = 0.96), but the titers for the SEAP
assay were an order of magnitude higher (mean = 16-fold,
range = 7–27-fold) than those observed with the focus assayg serum from the HPV16 VLP phase I clinical trial
seudovirus neutralization
Optiprep purified
2 3 Average HPV16 HPV18
10,240 10,240 10,240 40,960 <40
10,240 10,240 13,653 30,720 <40
10,240 10,240 13,653 20,480 <40
20,480 20,480 27,307 61,440 <40
<40 <40 <40 <40 <40
10,240 20,480 17,067 20,480 <40
81,920 40,960 68,267 163,840 <40
2560 2560 3413 5120 <40
<40 <40 <40 <40 <40
20,480 20,480 40,960 61,440 <40
20,480 20,480 27,307 40,960 <40
10,240 5120 8533 10,240 <40
16,970 30,500
t-neutralizing titer, which was defined as 50% inhibition of the amount of
tric mean titers.
viously published (Harro et al., 2001; Pastrana et al., 2001).
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good correlation with the ELISAs (q = 0.95, linear weighted
j = 0.74 {95% CI = 0.39–1.0}), and the increased sensi-
tivity of the SEAP assays resulted in the neutralization titers
obtained by this assay being comparable to the ELISA titers.
The crude HPV16 pseudovirion preparations also contain
noninfectious empty VLPs (Buck et al., 2004). Several
batches of crude preparations were tested to determine if
the pseudovirions performed similarly. When crude prepa-
rations were diluted to obtain 30–50 RLUs, the endpoint
neutralization titer with V5 was consistently found to be
about 2.5  106 (data not shown). Because VLPs may
contain neutralization epitopes, their presence would be
expected to reduce the apparent neutralizing titer of sera
by competing with pseudovirions for adsorption of neutral-
izing antibodies. Given that the use of Optiprep density
fractionation can partially separate empty VLPs from DNA-
containing pseudovirions (C.B. Buck et al., 2004), we
sought to determine whether Optiprep fractionation might
increase the sensitivity of the SEAP neutralization assay. We
found that neutralization titers were an average of 1.9-fold
higher for the 12 volunteers tested with Optiprep purified
pseudovirus (Table 2) (P = 0.003). However, Optiprep
purification resulted in a 97% loss of HPV16 pseudovirus
titer. Similar losses in titer were seen after Optiprep purifi-
cation of HPV18 (development of HPV18 pseudovirions is
described below), but not of BPV1 pseudovirus stocks.
Despite the reduction in titer, the high initial yield of the
production system made it possible to harvest enough
Optiprep purified material for approximately 4000 individ-
ual tests from a single 162-cm2 flask of transfected 293TT
cells. To ensure that different batches of pseudovirions had
similar ratios of VLP/pseudovirions, the preparations were
normalized for RLUs yielded, analyzed by SDS-PAGE,
silver stained to determine L1 content, and endpoint titers
determined using monoclonal V5 for HPV16, monoclonal
5B6 for BPV1, and a rabbit polyclonal serum for HPV18.
Endpoint titers with V5 for HPV16 were 2.5 107, with 5B6
for BPV1 were 1 105, and with rabbit polyclonal serum for
HPV18 were 1  106. For the experiments described in this
paper using Optiprep purified stocks, a single batch of
pseudovirions was used for HPV16, BPV1, and HPV18; 3,
1, and 0.2 ng, respectively, of L1 were added per well to
yield about 40 RLUs. To further examine the specificity of
the neutralization assay, we tested sera from a panel of
vaccinees in a SEAP BPV1 pseudovirus assay as well as
the SEAP HPV16 assay with crude- and Optiprep-purified
pseudovirus preparations. Because BPV1 is divergent from
HPV and human exposure to BPV1 probably occurs only
rarely, human sera would not be expected to have significant
anti-BPV1 neutralizing capacity. The limited amount of the
sera used for generating the data in Table 2 made it necessary
to use sera from 17 participants in our Phase II HPV16 L1
VLP vaccine trial (Harro et al., unpublished). As with sera
from vaccinees in the Phase I trial, the HPV16 ELISA and
SEAP HPV16 neutralization titers of sera from vaccinees inthe Phase II trial were similar to each other (data not shown).
A few of the sera from the Phase II vaccinees were able to
neutralize a crude preparation of SEAP BPV1 pseudovirus at
a dilution of 1:20, but not at higher dilutions (data not
shown). This sporadic nonspecific low-titer ‘‘neutralizing’’
activity was also observed with Optiprep-purified prepara-
tions of SEAP BPV1 pseudovirus. In addition, low neutral-
izing activity was detected in some preimmune sera from
other sources (rabbits, mice, sheep, and human sera from
other studies, see results below and data not shown). From
these results, we conclude that the observed inhibition of
SEAP BPV1 pseudovirion infection does not result from
cross-neutralizing antibodies induced by HPV16 L1 VLP
vaccination, but rather from a nonspecific factor(s) present in
some sera. Heat inactivation, repeated cycles of freeze
thawing, centrifugation at 16000  g, and preabsorption of
the sera with heterologous VLPs failed to eliminate the
nonspecific inhibition of infectivity (data not shown). Except
for one serum (see section on Detection of neutralizing
antibodies in sera from unvaccinated women), we have not
observed cross-species inhibition of pseudovirus infection at
dilutions above 1:40.
The specificity of the HPV16 neutralization titers was
also examined by developing an analogous SEAP HPV18
pseudovirus neutralization assay. Despite the presence of
high HPV16 neutralization titers (5100–163000 using
HPV16 SEAP Optiprep-purified pseudovirions), none of
the sera from Phase I HPV16 VLP vaccinees, when diluted
to 1:40 or higher, neutralized SEAP HPV18 pseudovirus,
confirming the type-specific nature of the neutralizing anti-
bodies induced by the HPV16 VLP vaccine (Table 2). The
sera from the vaccinees were also studied with a standard
HPV18 ELISA, which detected positive titers that were 4–
64-fold lower than their HPV16 ELISA titers (Table 2). This
positive result with the HPV18 ELISA is not unexpected, as
VLPs contain cross-reactive linear epitopes that are non-
neutralizing. The contrast between the positive HPV18
ELISA data and the negative HPV18 neutralization results
demonstrates the greater type specificity of the neutraliza-
tion assay.
Detection of neutralizing antibodies in sera from
unvaccinated women
To investigate whether the greater sensitivity of the
SEAP pseudovirus neutralization assay might make it useful
for detecting type-specific neutralizing antibody responses
following genital tract HPV infection, we tested sera from a
cohort of Danish women whose cervical HPV DNA status
(Kjaer et al., 1996) and HPV16 ELISA reactivity (Kjaer et
al., 2001) were known. The cohort was divided into six
groups (Table 3). The first group consisted of women who,
when they entered the study, were virgins and initially tested
negative both for genital HPV DNA and HPV16 ELISA
reactivity (Group 1A), but who subsequently became pos-
itive for genital HPV DNA following initiation of sexual
Table 3
Neutralization of HPV16 and BPV1 and HPV18 with serum from a natural
history study
ID # DNA ELISA Neutralization
HPV16 HPV18 HPV16 BPV1 HPV18
Group 1A 1A-1 Neg Neg Neg 20 <40 <40
virgins 1A-2 Neg Neg Neg 40 <40 <40
1st visit 1A-3 Neg Neg Neg 20 <40 <40
1A-4 Neg Neg Neg 40 <40 <40
1A-5 Neg Neg Neg 40 <40 <40
1A-6 Neg Neg Neg <20 <40 <40
1A-7 Neg Neg Neg <40 <40 <40
1A-8 Neg Neg Neg 40 <40 40
1A-9 Neg Neg Neg 40 <40 40
Group 1B 1B-1 X* 640 Neg 2560 <40 <40
initiated 1B-2 16 Neg 160 160 40 160
sexual 1B-3 16 Neg Neg 400 <40 40
activity, 1B-4 16 Neg 160 <40 <40 <40
2nd visit 1B-5 16 640 Neg 10,240 <40 160
1B-6 56 Neg Neg 640 <40 160
1B-7 16,18 Neg 160 40 <40 40
1B-8 16 Neg Neg 40 <40 <40
1B-9 16,18,35 Neg 160 40 <40 40
Group 2 2-1 Neg Neg NT 40 <40 NT
16DNA/ 2-2 33 Neg NT 40 <40 NT
16ELISA 2-3 Neg Neg NT <20 <40 NT
2-5 Neg Neg NT 40 <40 NT
2-6 Neg Neg NT 40 <40 NT
2-7 Neg Neg NT 40 <40 NT
2-8 Neg Neg NT 40 <40 NT
2-9 Neg Neg NT 160 <40 NT
2-10 Neg Neg NT <40 <40 NT
2-11 Neg Neg NT 40 40 NT
Group 3 3-1 16 160 NT 640 <40 NT
16DNA+/ 3-3 16 40 NT 640 40 NT
16ELISA+ 3-4 16 160 NT 640 <40 NT
3-5 16,31 160 NT 40 <40 NT
3-6 16 160 NT 640 40 NT
3-7 16,33,45 160 NT 160 40 NT
3-8 16 160 Neg 2560 40 <40
3-10 16 2560 NT 400 160 NT
Group 4 4-1 16,52 Neg NT 160 <40 NT
16DNA+/ 4-2 16 Neg NT 40 <40 NT
16ELISA 4-3 16 Neg NT 160 <40 NT
4-4 16,18 Neg NT 160 <40 NT
4-5 16 Neg NT 160 <40 NT
4-7 16 Neg NT 160 <40 NT
4-8 16,56 Neg NT 160 <40 NT
4-9 16,18 Neg NT 40 <40 NT
4-10 16 Neg NT 160 <40 NT
Group 5 5-1 Neg 40 NT 640 <40 NT
16DNA/ 5-2 56 10,240 40 10,240 <40 40
16ELISA+ 5-3 Neg 160 NT 640 40 NT
5-4 Neg 160 NT 40 <40 NT
5-6 Neg 640 NT 40 <40 NT
5-7 35,58 160 NT 160 40 NT
5-8 Neg 160 40 2560 <40 40
5-9 31 640 NT 640 <40 NT
Group 6 6-1 18,33 Neg 40 <40 <40 40
18 DNA+/ 6-2 18 Neg 640 40 <40 640
16 DNA/ 6-3 18 Neg Neg 40 40 40
16 ELISA 6-4 18 Neg 160 160 <40 160
6-5 18,45 Neg 640 40 <40 2560
6-6 18 Neg 40 40 <40 160
6-7 18 Neg Neg 40 <40 40
6-8 18 Neg 40 40 <40 40
Table 3 (continued)
ID # DNA ELISA Neutralization
HPV16 HPV18 HPV16 BPV1 HPV18
Group 6 6-9 11,18 Neg 40 160 40 160
18 DNA+/ 6-10 18 Neg 40 40 <40 160
16DNA/
16 ELISA
Note. For the neutralization assays, titers at or below 40 (depicted in italics)
were considered negative. NT denotes not tested.
X* denotes an untyped HPV DNA.
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sexually active women who were negative both for HPV16
DNA and HPV16 ELISA (Group 2), positive for both
assays (Group 3), positive for one assay but not the other
(Groups 4 and 5), or positive for HPV18 DNA but negative
for HPV16 DNA and HPV16 ELISA (Group 6).
Approximately 10 women from each group were chosen
at random for evaluation in the SEAP HPV16 and BPV1
neutralization assays. We also performed HPV16 ELISAs
on the samples. Of the sera we analyzed by quantitative
ELISA, most (54/60) gave results that were concordant with
previously published ELISA results, which used a qualita-
tive assay (Kjaer et al., 2001). Sera from the six volunteers
whose endpoint titer and qualitative ELISAs were discor-
dant were not included in the comparisons with the SEAP
neutralization assay.
To maximize sensitivity, the sera were tested using
Optiprep-purified pseudovirus. The BPV1 pseudovirus
was included as specificity control. Of the 60 volunteers
tested, 59 had anti-BPV1 neutralization titers of 40 or
less. One individual (3-10) had an anti BPV-1 titer of
160 (Table 3). It is not known whether this volunteer
might have developed an authentic anti-BPV1 response to
BPV1 exposure or had an unusually high serum concen-
tration of a nonspecific inhibitor(s). Based on these
results, sera were considered positive for HPV neutrali-
zation if their SEAP HPV neutralization titer was greater
than 40 and was also at least 4-fold higher than in the
BPV1 assay.
Using these criteria, 27 of the 63 (43%) sera from the
natural history study were considered HPV16 seropositive
by the neutralization assay compared to the 10 of 63 (16%)
by ELISA (P = 0.0002). The j between these two tests was
0.26 (95% CI = 0.06–0.46) and the percent agreement was
67%. When the analysis was restricted to those subjects who
were HPV16 DNA negative at the time the sera were
collected, 14 of 46 (30%) sera from the natural history
study were considered HPV16 seropositive by the neutral-
ization assay compared to the 2 of 46 (4%) by ELISA (P =
0.0005). The j between these two tests was 0.19 (95% CI =
0.02–0.36) and the percent agreement was 74%. These
results suggest that the neutralization assay is more sensi-
tive, but leaves open the possibility that it might be less
specific than the ELISA. This issue was therefore explored
by studying the individual groups.
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women were negative in the SEAP HPV16 neutralization
assay. Sera from these same women had also been collected
at a second visit, after they had become sexually active and
had acquired cervical HPV DNA (Group 1B). HPV16 DNA
was detected in Pap specimens from seven of the women,
and a different HPV genotype was detected in specimens
from the other two women. In the HPV16 ELISA, only two
women seroconverted, one who was HPV16 DNA positive
and one infected with an unknown type. By comparison,
five of nine (56%) sera were considered positive in the
SEAP HPV16 neutralization assay. The positive results
included both of the sera that were also positive by ELISA,
two additional cases that were HPV16 DNA positive, and
one case that was positive for HPV56 DNA.
Although the women in Group 2 had been sexually
active, they were expected to be at low risk for having
anti-HPV16 neutralizing antibodies because their sera were
HPV16 VLP ELISA negative and their cervical samples
were HPV DNA negative (Table 3). Consistent with this
prediction, only 1 of the 10 women in this group was
positive in the HPV16 neutralization assay. This woman
gave a history of having six sexual partners.
The women in Group 3 were expected to be positive in
the neutralization assay because they were positive both
for HPV16 DNA and HPV16 ELISA. Indeed, seven of the
eight women (87.5%) in Group 3 were positive for
neutralizing antibodies. Most of the HPV16-neutralizing
titers were higher than the corresponding HPV16 ELISA
titers. A notable exception was subject 3–10, who had a 6-
fold higher ELISA titer; interestingly, she was also the
only subject with a detectable anti-BPV1 neutralizing titer.
The trend towards higher sensitivity of the HPV16 neu-
tralization assay compared to the HPV16 ELISA was also
borne out in Group 4, with seven of its nine subjects
(77.8%) being positive for HPV16 neutralization, even
though all were negative by HPV16 ELISA. The women
in Group 5 (HPV16 ELISA positive/HPV16 DNA nega-
tive) presumably had successfully cleared their HPV
infections before enrollment in the study. Sera from six
of the eight subjects in this group were HPV16 neutrali-
zation positive. The two subjects whose neutralization
assays were negative (5-4 and 5-6) had low to intermediate
ELISA titers (160 and 640, respectively).
We also carried out a smaller pilot characterization of the
SEAP HPV18 neutralization assay. As with the HPV16
neutralization assay, all nine sera from the virgins (Table 3,
group 1A) were negative in the HPV18 neutralization assay.
At their second visit, after the women had become positive
for HPV DNA, sera from three of the women were HPV18
neutralization positive, although they were not the two
women in whom HPV18 DNA had been detected (1B-7
and 1B-9). To further characterize the HPV18 neutralization
assay, women in Group 6 were examined because they were
positive for HPV18 DNA but were negative both by HPV16
DNA and by HPV16 ELISA (Table 3). In this group, whichhad not previously been tested for HPV18 serologic
responses, 8 of 10 were HPV18 ELISA positive, and 6 of
10 were HPV18 neutralization positive (all 6 were HPV18
ELISA positive) (Table 3). For the six sera where both the
HPV18 ELISA and HPV18 neutralization results were
positive, the neutralization titer was either the same (2/6)
or 4-fold higher (4/6). The two subjects whose serum was
positive in the HPV18 ELISA but negative in the HPV18
neutralization assay had low ELISA titers (40).
To further explore the type specificity of the two
neutralization assays, we tested the HPV18 assay with
sera from the three women from the remaining groups who
had HPV16 neutralization titers of 2560 or higher (Table
3; subjects 3-8, 5-2, and 5-8). None had detectable HPV18
neutralizing activity, although two were HPV18 ELISA
positive at a titer of 40 (subjects 5-2 and 5-8). Taken
together, the results argue against the possibility that the
HPV16 and HPV18 neutralization assays are measuring
cross-neutralizing antibodies in women who were positive
in both neutralization assays. It seems more likely that
women whose sera were positive in both neutralization
assays had been exposed at some point to both HPV types.Discussion
Here we report the generation and characterization of
papillomavirus pseudovirus-based neutralization assays for
HPV16, HPV18, and BPV1. In this initial characterization,
the neutralization assays appear to be at least as sensitive
as, and possibly more HPV genotype-specific than, a
standard VLP-based ELISA. In addition, SEAP-based
HPV neutralization assays directly measure the activity
of antibodies that may be the most relevant to vaccine and
natural history studies. The neutralization assay is run in
96-well plates, where it can be performed with a few
microliters of sample, which is often available in limited
quantities. The assay is amenable to large-scale production,
and possibly to automation.
The assay represents an application of our recently
described method for generating high-titer papillomavirus
pseudoviruses in mammalian cells (Buck et al., 2004). The
pseudovirus production method depends in part on the high-
level expression of the two viral structural proteins, L1 and
L2, whose authentic genes have been found to be poorly
expressed in monolayer cultures of mammalian cells. This
poor expression may be attributable to the presence of
multiple negative regulatory elements (see discussion and
references in Buck et al., 2004). One successful approach to
overcoming this problem depends on the silent conversion
of papillomavirus codons to those most frequently found in
highly expressed mammalian proteins (Leder et al., 2001;
Zhou et al., 1999) (Buck et al., 2004) (Liu et al., 2002). In
this report, we have codon-modified the L1 and L2 genes of
HPV18 using the codon modification strategy described by
Buck et al. The successful application of codon modification
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et al., 2004), HPV16 (Leder et al., 2001), and HPV18 (this
report) suggests that it should be an effective strategy for
allowing high-level expression of the structural genes of
other papillomaviruses.
The SEAP-expressing pseudoviruses used in the neutral-
ization assay can be used in the form of crude cell lysates or
following partial purification in an Optiprep gradient. The
sensitivity of the crude preparations appears to be similar to
that of the standard VLP ELISA, while the Optiprep-
purified material has 2-fold greater sensitivity, without
apparent loss of specificity. The crude preparations can be
used where high titer responses are expected, as in sera from
VLP vaccine trials. The Optiprep purification preferentially
removes some of the noninfectious particles that can com-
pete with the infectious pseudovirions for binding neutral-
izing antibodies. Its modestly improved sensitivity may be
desirable for samples expected to have low neutralizing
activity, such as serum or mucosal samples in natural
infection studies or mucosal samples from vaccine trials.
For the Optiprep-purified material, we estimate that we have
used about 1000–2500 virion equivalents of L1 per cell. By
comparison, 25000 viral particles/cell and 150000 particles/
cell were previously reported for two HPV11 neutralization
assays (Leiserowitz et al., 1997; Yeager et al., 2000). In
contrast to previous neutralization assays, the production of
infectious particles should not be limiting because crude
extracts from a single 162-cm2 flask can produce enough
SEAP pseudoviruses for 150000 wells. Optiprep purifica-
tion of HPV16 and HPV18 pseudovirions is associated with
a 1.5 log reduction in yield. However, the purification
procedure we have used in this report was optimized for
use with BPV1 pseudoviruses (C.B. Buck et al., in press,
Journal of Virology). Further optimization of the procedure
might reduce the loss of titer.
One limitation of the SEAP neutralization assay is the
nonspecific inhibition of pseudovirus activity that was
observed with low dilutions of serum (1:10–1:40). Nonspe-
cific inhibition of pseudovirus infection has been reported
for at least one other cell-based neutralization assay (Yeager
et al., 2000). It would be useful to identify and eliminate the
factor(s) responsible for this inhibition, with the goal of
increasing the sensitivity of the assay by detecting specific
neutralization in lower dilutions of serum.
Immunodominant neutralizing antibodies are generally
directed against L1 conformational epitopes that are type-
specific (Christensen and Kreider, 1990, 1991; Christensen
et al., 1990; Ghim et al., 1991; Kirnbauer et al., 1994; Roden
et al., 1995), although limited cross-reactivity has been
observed among closely related types such as HPV16 and
33, HPV18 and 45, and HPV6 and 11 (Christensen et al.,
1994; Combita et al., 2002; Giroglou et al., 2001; Roden et
al., 1996b; White et al., 1998). Because the VLP-based
ELISA is more likely to recognize non-neutralizing linear
epitopes that are more cross-reactive between HPV geno-
types, the neutralization assay may be substantially moregenotype-specific than the standard ELISA. The greater type
specificity of the HPV18 neutralization assay compared with
the HPV18 ELISA was seen in the HPV16 VLP vaccinees.
Sera from vaccinated individuals with very high anti-HPV16
neutralization titers were unable to neutralize HPV18 pseu-
dovirions, while the same sera were positive in the HPV18
ELISA. We do not have sera from individuals vaccinated
only with HPV18 VLPs. However, one woman, who was
naturally infected with HPV18 and had anti-HPV18 neutral-
izing titers of 2560, was negative for HPV16 neutralization.
This result, plus a lack of relationship between HPV16
neutralization titer and HPV18 neutralization titer in the sera
from the HPV natural history cohort, suggests that the
HPV16 neutralization assay is also type-specific.
The limited cross-reactivity of L1 neutralizing antibodies
has led vaccine researchers to conclude that protection from
VLPs will be relatively type-specific. This characteristic is
expected to lead to the development of multivalent VLP
vaccines, as multiple HPV types are implicated in benign
and malignant HPV infections (Bosch and de Sanjose, 2003;
Bosch et al., 1995). The tendency of the standard ELISA for
a heterologous HPV genotype to yield potentially false-
positive results is likely to become progressively more
important as the number of HPV genotypes in the vaccine
is increased. Probable false-positive VLP ELISA results can
be overcome with the SEAP neutralization assay, or with a
VLP-based biochemical assay where a neutralizing mono-
clonal antibody competes with serum antibodies for binding
to VLPs (Opalka et al., 2003; Yeager et al., 2000). While
both assays are more genotype-specific than the standard
ELISA, the biochemical assay may not detect classes of
neutralizing antibodies whose binding to VLPs is not
inhibited by the neutralizing monoclonal antibody (Wang
et al., 1997). It is also possible that a subset of non-
neutralizing L1 antibodies could sterically hinder VLP
binding of the labeled neutralizing monoclonal antibody,
thereby producing false-positive results.
The SEAP neutralization assays may also find applica-
tion in the development of L2-dependent vaccines, which
have the potential of inducing cross-reactive neutralizing
antibodies (Kawana et al., 1999; Roden et al., 2000). The
production of pseudoviruses depends upon the presence of
L2 (C.B. Buck et al., in press, Journal of Virology), and
preliminary analysis indicates that they can be neutralized
by anti-L2 sera (unpublished data).
Seroconversion, as measured by VLP ELISA, does not
occur in all natural infections, may be delayed by several
months relative to the initial detection of genital tract HPV
DNA, and is more likely to occur in persistent HPV
infection (reviewed in (Konya and Dillner, 2001)). It was
therefore of interest to evaluate the relationship between the
presence of cervical HPV DNA and seropositivity in the
HPV16 and HPV18 neutralization assays.
Among women with prevalent (mostly asymptomatic)
HPV16 or 18 infections (Table 3, Groups 3, 4, and 6), 19 of
27 (73%) scored positive in the corresponding neutralization
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al. (2002), who detected HPV16 pseudovirus neutralizing
antibodies in 6/7 women with asymptomatic HPV16 infec-
tion. While most neutralizing titers in our natural infection
study were in the 160–640 range, several of the women had
titers of 2560–10250 (Table 3), overlapping the lower range
of titers in VLP-vaccinated women (Table 2). In previous
studies attempting to detect neutralizing antibodies in HPV-
infected women, the sera were tested at only a single low
dilution of 1:10 (Wang et al., 1997), 1:20 (Bousarghin et al.,
2002; Leiserowitz et al., 1997), 1:100 (Kawana et al., 2002),
or 1:160 (Smith et al., 1995).
Our results suggest that the HPV16 neutralization assay,
using Optiprep-purified pseudovirions, is possibly more
sensitive than the HPV16 ELISA. The greater sensitivity
was seen most strikingly in the groups of subjects who were
selected for study because they were HPV16 DNA positive
but HPV16 ELISA negative. Among this group, seven of
nine were positive in the HPV16 neutralization assay.
However, we note that the SEAP-based HPV neutralization
titers among these discordant results were low (160), and
thus we cannot rule out false positivity as the consequence
of an arbitrary positive cutpoint. Moreover, this same trend
was not observed among the smaller set of women with
prevalent HPV18 infections, where 6/8 HPV18 ELISA-
positive women were neutralization positive compared with
0/2 women who were ELISA negative.
Analysis of larger and more varied study populations
will be needed to more precisely establish the relationship
among neutralization titers, genital tract HPV DNA, and
VLP ELISA reactivity in various types of human subjects.
Nevertheless, this initial report establishes the SEAP HPV
pseudovirus neutralization assay as a specific, sensitive,
and practical method for evaluating potentially protective
antibody responses in natural history and prophylactic
vaccine studies.Materials and methods
Cell lines
C127 clone C (Dvoretzky et al., 1980) and HaCaT cells
(Boukamp et al., 1988) were grown in complete Dulbec-
co’s modified Eagle medium (DMEM) (Invitrogen) con-
taining 10% heat-inactivated fetal bovine serum (HyClone).
293H and 293TT (Buck et al., 2004) cells were grown in
the same medium supplemented with 1% Glutamax and
1% nonessential amino acids (Invitrogen).
Plasmids
Nucleotide sequences of plasmids constructed for the
manuscript can be found at http://ccr.cancer.gov/Staff/Links.
asp?StaffID=443. pSEAP2Basic and pSEAP2Control were
purchased from BD Biosciences Clontech. Plasmid con-structs 16L1h and 16L2h expressing codon-modified
HPV16 L1 and L2 genes were kindly provided by Martin
Mu¨ller (Leder et al., 2001). For bovine papillomavirus type
1 (BPV1) codon modified genes, we used a single plasmid,
pSheLL, which codes for both BPV1 L1 and BPV1 L2
(Buck et al., 2004). We used the As Different As Possible
(ADAP) strategy (C.B. Buck et al., in press, Journal of
Virology) to codon-modify HPV18 L1 and L2 open reading
frames (GenBank accession numbers AY383628 and
AY383629). Based on the successful modification of
HPV16 (Leder et al., 2001) and of HPV18 and BPV1 by
ADAP, we have created a set of rules that can be applied to
modify the late gene codons of other HPV types. A
computer program that calculates modifications according
to these rules is available at http://genome.nci.nih.gov/pub-
lications/papilloma_ADAP.html. The genes were chemical-
ly synthesized by Blue Heron Biotechnologies, confirmed
by sequencing, and provided in their pBHBCMV mamma-
lian expression vector. The resulting codon-modified 18L1
and 18L2 constructs were named peL1bhb and peL2bhb,
respectively. The codon-modified 18L1 ORF was subcloned
into vector puL1fB, which contains an EF1a promoter. The
puL1fB construct was made as follows: the Toll-like recep-
tor gene of pUNO-hTLR09 (Invitrogen) was replaced with
the ORF of codon-modified HPV 16 L1 from p16L1h to
make puL1B. Enhanced green fluorescent protein (GFP)
(Clontech) was then inserted into this plasmid to generate
puL1fB. To build peL1fB, 16L1 was removed from puL1fB
and replaced with codon-modified 18L1 from peL1bhb.
GFP reporter plasmid pYafW was generated by inserting a
fragment containing GFP into a modified version of pYafB.
pYafB was generated by replacing the BPV1 URR and
HSV TK polyA signal of pSU-5697 (Buck et al., 2004)
with a BstBI–DraI fragment from the BPV1 genome
encoding a putative packaging signal (Zhao et al., 1999).
For reporter plasmids pYSEAP and p2CMVSEAP, secreted
alkaline phosphatase was taken out of pSEAP2Basic and
placed into pYafB or pCINeo (Promega) backbones,
respectively.
Generation of pseudoviruses
Pseudoviruses were generated by cotransfection of
293TT cells as described elsewhere (C.B. Buck et al., in
press, Journal of Virology). Briefly, 20 million 293TT cells
were plated 16 h before transfection in 162-cm2 flasks.
Lipofectamine 2000 (Invitrogen) was used for transfection,
as directed by the manufacturer, using 175 Al of the lipid
reagent and a total of 80 Ag of plasmid DNA per flask. For
the production of HPV16 pseudovirus, the cells were
transfected with 27 Ag each of pYSEAP, p16L1h, and
p16L2h. For HPV18, cells were transfected with 27 Ag
each of pYSEAP, peL1fB, and peL2bhb. For BPV1, we
used 40 Ag each of pSheLL and pYSEAP. After 4–6 h, the
media on the transfected cells were replaced. Cells were
split into two 225-cm2 flasks at 20–24 h and harvested
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trypsinized and rinsed with Dulbecco’s (D) PBS (Invitro-
gen). Pellets were resuspended at 50 million cells/ml in
DPBS supplemented with an additional 9.5 mM MgCl2.
Brij 58 and Benzonase (Sigma) were added to a final
concentration of 0.5% each, and Plasmid-Safe ATP-Depen-
dent DNase was at 0.2% (Epicentre). The mixture was
incubated at 37 jC for 45 min. NaCl was adjusted to 850
mM and the mixture placed at 4 jC for 10 min, then
clarified by spinning at 1500  g for 10 min at 4 jC.
Supernatants were aliquoted into siliconized microcentri-
fuge tubes (BioPlas) and frozen at 80 jC. For purified
preparations, the clarified supernatant was loaded on top of
a 27,33,39% Optiprep (Sigma) density gradient that was
preformed at room temperature for 4 h. The material was
centrifuged at 234000  g for 3 h at 16 jC in an SW50.1
rotor (Beckman) and collected by bottom puncture of the
tubes. Fractions were inspected for purity on 10% SDS–
Tris–glycine gels (Bio-Rad), titrated on 293 TT cells to test
for infectivity by SEAP detection, then pooled and frozen
at 80 jC until needed.
Neutralization assay
Neutralization buffer was prepared by mixing DMEM
without phenol red, 10% heat-inactivated FBS, 1% gluta-
mate, 1% nonessential amino acids, 1% penicillin–strep-
tomycin–fungizone, and 10 mM HEPES (Invitrogen).
293TT cells were preplated 3–4 h in advance in 96-well
tissue culture-treated flat bottom plates (Corning-Costar) at
30000 cells/well in 100 Al neutralization buffer. To avoid
evaporation, perimeter wells were filled with medium.
Crude pseudovirus preparations were diluted 10000-fold,
and Optiprep-purified material was diluted 150–400-fold.
At these dilutions, target cells typically generated enough
secreted alkaline phosphatase (SEAP) for an output read-
ing of 30–70 relative light units (RLUs) (see below).
Diluted pseudovirus stocks (80 Al/well) were placed in
96-well nontreated sterile, polystyrene plates (Nalge-
Nunc), combined with 20 Al of diluted serum, and placed
on ice for 1 h. The 100-Al pseudovirus–antibody mixture
was transferred onto the preplated cells and incubated for
68–72 h. At the end of the incubation, 50 Al of superna-
tant was harvested and clarified at 1500  g for 5 min.
The SEAP content in the clarified supernatant was deter-
mined using the Great ESCAPE SEAP Chemilumines-
cence Kit (BD Clontech) as directed by the manufacturer,
with 15 Al of the clarified supernatant. Twenty minutes
after the substrate was added, samples were read in either
white Microlite 1 (Dynex) or Optiplate-96 (Perkin-Elmer)
opaque 96-well plates for 0.20 s/well using an MLX
Microplate Luminometer (Dynex Technologies) set at
Glow-Endpoint. Serum neutralization titers were defined
as the reciprocal of the highest dilution that caused at least
a 50% reduction in SEAP activity. A serum was consid-
ered to be positive for neutralization in the HPV16 orHPV18 assay if it was neutralizing at a dilution at least 4-
fold higher than the titer observed in the BPV1 neutrali-
zation assay.
Monoclonal antibodies and sera
Monoclonal antibody V5 was kindly provided by Neil
Christensen (Christensen et al., 1996a). Monoclonal Anti-
body 5B6 was previously generated in our laboratory
(Roden et al., 1994). Sera from vaccinated individuals
were from a phase I HPV16 L1 VLP vaccine trial (Harro
et al., 2001) and an unpublished phase II trial. Sera from
naturally infected women were from a prospective cohort
study of HPV and cervical neoplasia in Copenhagen (Kjaer
et al., 1996). Reactivity for this group had been previously
determined in an HPV16 ELISA assay (Kjaer et al., 2001),
sera was analyzed at a single dilution of 1:10 and
classified as positive or negative compared to a pooled
standard. For this study, endpoint ELISA reactivity was
performed as described below.
ELISA
IgG-specific HPV16 L1 VLP-based enzyme-linked
immunosorbent assays (ELISAs) were performed in a
96-well plate format as described previously (Harro et
al., 2001). Four-fold serial dilutions of each serum were
assayed, starting at a dilution of 1:10. Sera were desig-
nated ELISA positive at a given dilution if the optical
density (OD) was greater than or equal to 0.2 and also
greater than or equal to the reactivity of a standard
pooled serum (Wideroff et al., 1995), which was assayed
on the same plate.
Statistical analysis
Spearman correlation coefficients (q) and linear weighted
kappa values (j) were calculated to evaluate reproducibility
of the titers for the SEAP neutralization assay on crude
preparations and to compare the titers among the SEAP
neutralization assays on Optiprep-purified pseudovirions,
the VLP ELISA, and the focus assay on subjects participat-
ing in the HPV16L1 VLP vaccine trials. Wilcoxon matched-
pair sign-rank test was used to test differences in median
titers. VLP ELISA and the SEAP neutralization assay test
results (seropositive or seronegative) on sera from the
natural history study were compared using McNemar’s v2
test, unweighed kappa values and percent agreement were
also calculated.Acknowledgments
This work was supported by the intramural research
program of the National Cancer Institute. We thank R.
Roden (The Johns Hopkins University) for his insight on
D.V. Pastrana et al. / Virology 321 (2004) 205–216 215using SEAP as a reporter and P. Day (NCI) for helpful
discussions and manuscript revisions.References
Bosch, F.X., de Sanjose, S., 2003. Chapter 1: human papillomavirus and
cervical cancer—Burden and assessment of causality. J. Natl. Cancer
Inst. Monogr. (31), 3–13.
Bosch, F.X., Manos, M.M., Munoz, N., Sherman, M., Jansen, A.M., Peto,
J., Schiffman, M.H., Moreno, V., Kurman, R., Shah, K.V., 1995. Prev-
alence of human papillomavirus in cervical cancer: a worldwide pro-
spective. J. Natl. Cancer Inst. 87, 796–802.
Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Mark-
ham, A., Fusenig, N.E., 1988. Normal keratinization in a spontane-
ously immortalized aneuploid human keratinocyte cell line. J. Cell
Biol. 106 (3), 761–771.
Bousarghin, L., Combita-Rojas, A.L., Touze, A., El Mehdaoui, S.,
Sizaret, P.Y., Bravo, M.M., Coursaget, P., 2002. Detection of neutral-
izing antibodies against human papillomaviruses (HPV) by inhibition
of gene transfer mediated by HPV pseudovirions. J. Clin. Microbiol.
40 (3), 926–932.
Breitburd, F., Kirnbauer, R., Hubbert, N.L., Nonnenmacher, B., Trin-Dinh-
Desmarquet, C., Orth, G., Schiller, J.T., Lowy, D.R., 1995. Immuniza-
tion with virus-like particles from cottontail rabbit papillomavirus
(CRPV) can protect against experimental CRPV infection. J. Virol. 69
(6), 3959–3963.
Buck, C.B., Pastrana, D.V., Lowy, D.R., Schiller, J.T., 2004. Efficient intra-
cellular assembly of papillomaviral vectors. J. Virol. 78 (2), 751–757.
Christensen, N.D., Kreider, J.W., 1990. Antibody-mediated neutralization
in vivo of infectious papillomaviruses. J. Virol. 64, 3151–3156.
Christensen, N.D., Kreider, J.W., 1991. Neutralization of CRPV infectivity
by monoclonal antibodies that identify conformational epitopes on in-
tact virions. Virus Res. 21 (3), 169–179.
Christensen, N.D., Kreider, J.W., Cladel, N.M., Patrick, S.D., Welsh, P.A.,
1990. Monoclonal antibody mediated neutralization of infectious hu-
man papillomavirus type 11. J. Virol. 64, 5678–5681.
Christensen, N.D., Kreider, J.W., Shah, K.V., Rando, R.F., 1992. Detection
of human serum antibodies that neutralize infectious human papilloma-
virus type 11 virions. J. Gen. Virol 73, 1261–1267.
Christensen, N.D., Kirnbauer, R., Schiller, J.T., Ghim, S.J., Schlegel, R.,
Jenson, A.B., Kreider, J.W., 1994. Human papillomavirus types 6 and
11 have antigenically distinct strongly immunogenic conformationally
dependent neutralizing epitopes. Virology 205, 329–335.
Christensen, N.D., Dillner, J., Eklund, C., Carter, J.J., Wipf, G.C., Reed,
C.A., Cladel, N.M., Galloway, D.A., 1996a. Surface conformational and
linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined
by monoclonal antibodies. Virology 223, 174–184.
Christensen, N.D., Reed, C.A., Cladel, N.M., Han, R., Kreider, H.W.,
1996b. Immunization with virus-like particles induces long-term pro-
tection of rabbits against challenge with cottontail rabbit papillomavi-
ruses. J. Virol. 70, 960–965.
Combita, A.L., Touze, A., Bousarghin, L., Christensen, N.D., Coursaget,
P., 2002. Identification of two cross-neutralizing linear epitopes within
the L1 major capsid protein of human papillomaviruses. J. Virol. 76
(13), 6480–6486.
Day, P.M., Lowy, D.R., Schiller, J.T., 2003. Papillomaviruses infect cells
via a clathrin-dependent pathway. Virology 307 (1), 1–11.
Dillner, J., 1999. The serological response to papillomaviruses. Semin.
Cancer Biol. 9 (6), 423–430.
Dvoretzky, I., Shober, R., Chattopadhyay, S.K., Lowy, D.R., 1980.
Focus assay in mouse cells for bovine papillomavirus. Virology
103, 369–375.
Fazel, N., Wilczynski, S., Lowe, L., Su, L.D., 1999. Clinical, histopatho-
logic, and molecular aspects of cutaneous human papillomavirus infec-
tions. Dermatol. Clin. 17 (3), 521–536 (viii).Galloway, D.A., 2003. Papillomavirus vaccines in clinical trials. Lancet,
Infect. Dis. 3 (8), 469–475.
Ghim, S., Christensen, N.D., Kreider, J.W., Jenson, A.B., 1991. Compar-
ison of neutralization of BPV-1 infection of C127 cells and bovine fetal
skin xenografts. Int. J. Cancer 49 (2), 285–289.
Giroglou, T., Sapp, M., Lane, C., Fligge, C., Christensen, N.D., Streeck,
R.E., Rose, R.C., 2001. Immunological analyses of human papilloma-
virus capsids. Vaccine 19 (13–14), 1783–1793.
Handsfield, H.H., 1997. Clinical presentation and natural course of ano-
genital warts. Am. J. Med. 102 (5A), 16–20.
Harro, C.D., Pang, Y.Y., Roden, R.B., Hildesheim, A., Wang, Z., Reynolds,
M.J., Mast, T.C., Robinson, R., Murphy, B.R., Karron, R.A., Dillner, J.,
Schiller, J.T., Lowy, D.R., 2001. Safety and immunogenicity trial in
adult volunteers of a human papillomavirus 16 L1 virus-like particle
vaccine. J. Natl. Cancer Inst. 93 (4), 284–292.
Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., Kanda, T., 1998. In
vitro construction of pseudovirions of human papillomavirus type 16:
incorporation of plasmid DNA into reassembled L1/L2 capsids. J. Virol.
72 (12), 10298–10300.
Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., Kanda, T.,
1999. Common neutralization epitope in minor capsid protein L2
of human papillomavirus types 16 and 6. J. Virol. 73 (7),
6188–6190.
Kawana, K., Yasugi, T., Kanda, T., Kawana, Y., Hirai, Y., Yoshikawa, H.,
Taketani, Y., 2002. Neutralizing antibodies against oncogenic human
papillomavirus as a possible determinant of the fate of low-grade cer-
vical intraepithelial neoplasia. Biochem. Biophys. Res. Commun. 296
(1), 102–105.
Kirnbauer, R., Hubbert, N.L., Wheeler, C.M., Becker, T.M., Lowy, D.R.,
Schiller, J.T., 1994. A virus-like particle enzyme-linked immunosorbent
assay detects serum antibodies in a majority of women infected with
human papillomavirus type 16 [see comments]. J. Natl. Cancer Inst. 86
(7), 494–499.
Kirnbauer, R., Chandrachud, L., O’Neil, B., Wagner, E., Grindlay, G.,
Armstrong, A., McGarvie, G., Schiller, J., Lowy, D., Campo, M.,
1996. Virus-like particles of bovine papillomavirus type 4 in prophy-
lactic and therapeutic immunization. Virology 219, 37–44.
Kjaer, S.K., van den Brule, A.J., Bock, J.E., Poll, P.A., Engholm, G.,
Sherman, M.E., Walboomers, J.M., Meijer, C.J., 1996. Human papillo-
mavirus—The most significant risk determinant of cervical intraepithe-
lial neoplasia. Int. J. Cancer 65 (5), 601–606.
Kjaer, S.K., Chackerian, B., van den Brule, A.J., Svare, E.I., Paull, G.,
Walbomers, J.M., Schiller, J.T., Bock, J.E., Sherman, M.E., Lowy,
D.R., Meijer, C.L., 2001. High-risk human papillomavirus is sexually
transmitted: evidence from a follow-up study of virgins starting sexual
activity (intercourse). Cancer Epidemiol., Biomarkers Prev. 10 (2),
101–106.
Konya, J., Dillner, J., 2001. Immunity to oncogenic human papillomavi-
ruses. Adv. Cancer Res. 82, 205–238.
Koutsky, L.A., Holmes, K.K., Critchlow, C.W., Stevens, C.E., Paavo-
nen, J., Beckmann, A.M., ReRouen, T.A., Galloway, D.A., Vernon,
D., Kiviat, N.B., 1992. A cohort study of the risk of cervical intra-
epithelial neoplasia grade 2 or 3 in relation to papillomavirus infec-
tion. N. Engl. J. Med. 327, 1272–1278.
Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Barr, E., Alvarez,
F.B., Chiacchierini, L.M., Jansen, K.U., 2002. A controlled trial of a
human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (21),
1645–1651.
Leder, C., Kleinschmidt, J.A., Wiethe, C., Muller, M., 2001. Enhancement
of capsid gene expression: preparing the human papillomavirus type 16
major structural gene L1 for DNA vaccination purposes. J. Virol. 75
(19), 9201–9209.
Leiserowitz, G.S., Hall, K.S., Foster, C.A., Hitchcock, M.E., Christen-
sen, N.D., Heim, K., Smith, L.H., 1997. Detection of serologic
neutralizing antibodies against HPV-11 in patients with condyloma
acuminata and cervical dysplasia using an in vitro assay. Gynecol.
Oncol. 66 (2), 295–299.
D.V. Pastrana et al. / Virology 321 (2004) 205–216216Liu, W.J., Gao, F., Zhao, K.N., Zhao, W., Fernando, G.J., Thomas, R.,
Frazer, I.H., 2002. Codon modified human papillomavirus type 16 E7
DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tu-
mour activity. Virology 301 (1), 43–52.
Lowy, D.R., Howley, P.M., 2001. Papillomaviruses. In: Knipe, D.M., How-
ley, P.M. (Eds.), 4th ed. Fields Virology, vol. 2. Lippincott Williams and
Wilkins, Philadelphia, pp. 2231–2264. 2 vols.
Opalka, D., Lachman, C.E., MacMullen, S.A., Jansen, K.U., Smith, J.F.,
Chirmule, N., Esser, M.T., 2003. Simultaneous quantitation of antibod-
ies to neutralizing epitopes on virus-like particles for human papilloma-
virus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin.
Diagn. Lab. Immunol. 10 (1), 108–115.
Pastrana, D.V., Vass, W.C., Lowy, D.R., Schiller, J.T., 2001. An HPV16
VLP vaccine induces human antibodies that neutralize divergent var-
iants of HPV16. Virology 279 (1), 361–369.
Roden, R.B.S., Weissinger, E.M., Henderson, D.W., Booy, F., Kirnba-
uer, R., Mushinski, J.F., Lowy, D.R., Schiller, J.T., 1994. Neutrali-
zation of bovine papillomavirus by antibodies to L1 and L2 capsid
proteins. J. Virol. 68 (11), 7570–7574.
Roden, R.B., Hubbert, N.L., Kirnbauer, R., Breitburd, F., Lowy, D.R.,
Schiller, J.T., 1995. Papillomavirus L1 capsids agglutinate mouse eryth-
rocytes through a proteinaceous receptor. J. Virol. 69 (8), 5147–5151.
Roden, R.B.S., Greenstone, H.L., Kirnbauer, R., Booy, F.P., Jessie, J.,
Lowy, D.R., Schiller, J.T., 1996a. In vitro generation and type-specific
neutralization of a human papillomavirus type 16 virion pseudotype.
J. Virol. 70, 5875–5883.
Roden, R.B.S., Hubbert, N.L., Kirnbauer, R., Christensen, N.D., Lowy,
D.R., Schiller, J.T., 1996b. Assessment of the serological relatedness of
genital human papillomaviruses by hemagglutination inhibition. J. Virol.
70, 3298–3301.
Roden, R.B., Yutzy, W.I., Fallon, R., Inglis, S., Lowy, D.R., Schiller, J.T.,
2000. Minor capsid protein of human genital papillomaviruses contains
subdominant, cross-neutralizing epitopes. Virology 270 (2), 254–257.
Rossi, J.L., Gissmann, L., Jansen, K., Muller, M., 2000. Assembly of
human papillomavirus type 16 pseudovirions in Saccharomyces cerevi-
siae. Hum. Gene Ther. 11 (8), 1165–1176.
Schiffman, M.H., 1994. Epidemiology of cervical human papillomaviruses.
In: zur Hausen, H. (Ed.), Human Pathogenic Papillomaviruses. Spring-
er-Verlag, Heidelberg.
Schiller, J.T., Lowy, D.R., 2001. Papillomavirus-like particle based vac-
cines: cervical cancer and beyond. Expert Opin. Biol. Ther. 1 (4),
571–581.
Smith, L.H., Foster, C., Hitchcock, M.E., Leiserowitz, G.S., Hall, K., Isser-off, R., Christensen, N.D., Kreider, J.W., 1995. Titration of HPV-11
infectivity and antibody neutralization can be measured in vitro.
J. Invest. Dermatol. 105, 438–444.
Stanley, M.A., 2002. Human papillomavirus vaccines. Curr. Opin. Mol.
Ther. 4 (1), 15–22.
Stauffer, Y., Raj, K., Masternak, K., Beard, P., 1998. Infectious human
papillomavirus type 18 pseudovirions. J. Mol. Biol. 283 (3), 529–536.
Suzich, J.A., Ghim, S., Palmer-Hill, F.J., White, W.I., Tamura, J.K., Bell, J.,
Newsome, J.A., Jenson, A.B., Schlegel, R., 1995. Systemic immuniza-
tion with papillomavirus L1 protein completely prevents the develop-
ment of viral mucosal papillomas. Proc. Natl. Acad. Sci. U.S.A. 92,
11553–11557.
Touze, A., Coursaget, P., 1998. In vitro gene transfer using human papil-
lomavirus-like particles. Nucleic Acids Res. 26, 1317–1323.
Unckell, F., Streeck, R.E., Sapp, M., 1997. Generation and neutralization
of pseudovirions of human papillomavirus type 33. J. Virol. 71,
2934–2939.
Wang, Z., Christensen, N., Schiller, J.T., Dillner, J., 1997. A monoclonal
antibody against intact human papillomavirus type 16 capsids blocks
the serological reactivity of most human sera. J. Gen. Virol. 78 (Pt. 9),
2209–2215.
White, W.I., Wilson, S.D., Bonnez, W., Rose, R.C., Koenig, S., Suzich,
J.A., 1998. In vitro infection and type-restricted antibody-mediated
neutralization of authentic human papillomavirus type 16. J. Virol. 72
(2), 959–964.
Wideroff, L., Schiffman, M.H., Nonnemacher, B., Hubbert, N., Kirnba-
uer, R., Greer, C.E., Lowy, D.R., Lorincz, A.T., Manos, M.M.,
Glass, A.G., Scott, D.R., Serman, M.E., Kurman, R.J., Buckland,
J., Tarone, R.E., Schiller, J.T., 1995. Evaluation of seroreactivity to
HPV16 virus-like particle in an incident case-control study of cervical
neoplasia. J. Infect. Dis. 172, 1425–1430.
Yeager, M.D., Aste-Amezaga, M., Brown, D.R., Martin, M.M., Shah, M.J.,
Cook, J.C., Christensen, N.D., Ackerson, C., Lowe, R.S., Smith, J.F.,
Keller, P., Jansen, K.U., 2000. Neutralization of human papillomavirus
(HPV) pseudovirions: a novel and efficient approach to detect and
characterize HPV neutralizing antibodies. Virology 278 (2), 570–577.
Zhao, K.N., Frazer, I.H., Jun Liu, W., Williams, M., Zhou, J., 1999.
Nucleotides 1506–1625 of bovine papillomavirus type 1 genome
can enhance DNA packaging by L1/L2 capsids. Virology 259 (1),
211–218.
Zhou, J., Liu, W.J., Peng, S.W., Sun, X.Y., Frazer, I., 1999. Papillomavirus
capsid protein expression level depends on the match between codon
usage and tRNA availability. J. Virol. 73, 4972–4982.
